ASPI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ASP Isotopes Inc (ASPI) does not present a strong buy opportunity for a beginner, long-term investor at this time. The technical indicators are bearish, and while there are positive catalysts such as analyst optimism and growth in revenue, the company's financials still show significant losses. Additionally, there are no strong trading signals or recent congress trading data to support immediate action. Holding or waiting for further developments is the recommended approach.
The technical indicators for ASPI are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 41.896, and the moving averages (SMA_200 > SMA_20 > SMA_5) indicate a downward trend. The stock is trading near its pivot point of 5.436, with resistance levels at 5.776 and 5.986, and support levels at 5.096 and 4.886.
Analyst Derek Soderberg from Cantor Fitzgerald initiated coverage with an Overweight rating and a $13 price target, citing ASPI's advanced isotope-enrichment technology and potential value creation from the Renergen acquisition and quantum laser enrichment spinout.
Revenue increased by 349.53% YoY in Q3 2025, showing strong growth potential.
The U.S. Department of Energy's projection of increased demand for HALEU by 2050 could benefit ASPI in the long term.
The company's financials still show a net loss of -$12.87M in Q3 2025, despite improvement.
Gross margin dropped significantly by -68% YoY.
The technical indicators and moving averages are bearish, suggesting a lack of short-term momentum.
No significant insider or hedge fund activity, and no congress trading data available.
In Q3 2025, ASPI's revenue increased significantly by 349.53% YoY to $4.89M. However, the company reported a net loss of -$12.87M, which is an improvement of 77.05% YoY. EPS also improved to -0.15, up 25% YoY. Gross margin, however, dropped to 8.65%, a decline of -68% YoY, indicating challenges in operational efficiency.
Cantor Fitzgerald analyst Derek Soderberg initiated coverage with an Overweight rating and a $13 price target, highlighting ASPI's advanced isotope-enrichment technology, potential value creation from acquisitions, and its unique position in the isotope market.
